News & Updates

Mutations affect efficacy of avelumab in advanced endometrial cancer
Mutations affect efficacy of avelumab in advanced endometrial cancer
09 Jul 2024

Avelumab immunotherapy may perform poorly in advanced endometrial cancer (EC) patients with TP53 mutation but has positive effects in those with mutations of PTEN and ARID1A, suggest the results of the MITO END-3 trial.

Mutations affect efficacy of avelumab in advanced endometrial cancer
09 Jul 2024